WO2017136795A8 - Bacteria engineered to treat diseases associated with tryptophan metabolism - Google Patents

Bacteria engineered to treat diseases associated with tryptophan metabolism Download PDF

Info

Publication number
WO2017136795A8
WO2017136795A8 PCT/US2017/016609 US2017016609W WO2017136795A8 WO 2017136795 A8 WO2017136795 A8 WO 2017136795A8 US 2017016609 W US2017016609 W US 2017016609W WO 2017136795 A8 WO2017136795 A8 WO 2017136795A8
Authority
WO
WIPO (PCT)
Prior art keywords
diseases associated
tryptophan metabolism
treat diseases
bacteria engineered
bacteria
Prior art date
Application number
PCT/US2017/016609
Other languages
French (fr)
Other versions
WO2017136795A1 (en
Inventor
Dean Falb
Paul F. Miller
Jonathan W. KOTULA
Vincent M. ISABELLA
Adam B. FISHER
Yves Millet
Jose M. Lora
Original Assignee
Synlogic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/020530 external-priority patent/WO2016141108A1/en
Priority claimed from PCT/US2016/032565 external-priority patent/WO2016183532A1/en
Priority claimed from PCT/US2016/039444 external-priority patent/WO2016210384A2/en
Priority claimed from PCT/US2016/050836 external-priority patent/WO2017074566A1/en
Priority claimed from US15/260,319 external-priority patent/US11384359B2/en
Priority claimed from PCT/US2016/069052 external-priority patent/WO2017123418A1/en
Application filed by Synlogic, Inc. filed Critical Synlogic, Inc.
Priority to PCT/US2017/017552 priority Critical patent/WO2017139697A1/en
Priority to PCT/US2017/017563 priority patent/WO2017139708A1/en
Publication of WO2017136795A1 publication Critical patent/WO2017136795A1/en
Publication of WO2017136795A8 publication Critical patent/WO2017136795A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with dysregulated tryptophan metabolism are disclosed.
PCT/US2017/016609 2016-02-04 2017-02-03 Bacteria engineered to treat diseases associated with tryptophan metabolism WO2017136795A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2017/017552 WO2017139697A1 (en) 2016-02-10 2017-02-10 Bacteria engineered to treat diseases associated with hyperammonemia
PCT/US2017/017563 WO2017139708A1 (en) 2016-02-10 2017-02-10 Bacteria engineered to treat nonalcoholic steatohepatitis (nash)

Applications Claiming Priority (48)

Application Number Priority Date Filing Date Title
US201662291461P 2016-02-04 2016-02-04
US201662291470P 2016-02-04 2016-02-04
US201662291468P 2016-02-04 2016-02-04
US62/291,470 2016-02-04
US62/291,468 2016-02-04
US62/291,461 2016-02-04
US201662297778P 2016-02-19 2016-02-19
US62/297,778 2016-02-19
USPCT/US2016/020530 2016-03-02
PCT/US2016/020530 WO2016141108A1 (en) 2015-03-02 2016-03-02 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US201662305462P 2016-03-08 2016-03-08
US62/305,462 2016-03-08
US201662313691P 2016-03-25 2016-03-25
US62/313,691 2016-03-25
US201662314322P 2016-03-28 2016-03-28
US62/314,322 2016-03-28
US201662335940P 2016-05-13 2016-05-13
PCT/US2016/032565 WO2016183532A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to treat a disease or disorder
US62/335,940 2016-05-13
USPCT/US2016/032565 2016-05-13
US201662347508P 2016-06-08 2016-06-08
US201662347576P 2016-06-08 2016-06-08
US62/347,576 2016-06-08
US62/347,508 2016-06-08
US201662348620P 2016-06-10 2016-06-10
US201662348360P 2016-06-10 2016-06-10
US62/348,620 2016-06-10
US62/348,360 2016-06-10
US201662354682P 2016-06-24 2016-06-24
PCT/US2016/039444 WO2016210384A2 (en) 2015-06-25 2016-06-24 Bacteria engineered to treat metabolic diseases
USPCT/US2016/039444 2016-06-24
US62/354,682 2016-06-24
US201662362954P 2016-07-15 2016-07-15
US62/362,954 2016-07-15
US201662385235P 2016-09-08 2016-09-08
US15/260,319 2016-09-08
USPCT/US2016/050836 2016-09-08
PCT/US2016/050836 WO2017074566A1 (en) 2015-10-30 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US62/385,235 2016-09-08
US15/260,319 US11384359B2 (en) 2014-12-22 2016-09-08 Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
US201662423170P 2016-11-16 2016-11-16
US62/423,170 2016-11-16
US201662439871P 2016-12-28 2016-12-28
USPCT/US2016/069052 2016-12-28
PCT/US2016/069052 WO2017123418A1 (en) 2016-01-11 2016-12-28 Bacteria engineered to treat metabolic diseases
US62/439,871 2016-12-28
US201762443639P 2017-01-06 2017-01-06
US62/443,639 2017-01-06

Publications (2)

Publication Number Publication Date
WO2017136795A1 WO2017136795A1 (en) 2017-08-10
WO2017136795A8 true WO2017136795A8 (en) 2017-09-28

Family

ID=59500027

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/016609 WO2017136795A1 (en) 2016-02-04 2017-02-03 Bacteria engineered to treat diseases associated with tryptophan metabolism

Country Status (1)

Country Link
WO (1) WO2017136795A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2905525T3 (en) 2015-05-06 2022-04-11 Snipr Tech Ltd Alteration of microbial populations and modification of the microbiota
WO2020122430A1 (en) * 2018-12-10 2020-06-18 대화제약 주식회사 Expression system for hyaluronic acid production using non-pathogenic bacteria and hyaluronic acid production method using same expression system
EP3952864A4 (en) * 2019-03-08 2023-05-10 The Regents of the University of California Compositions and methods for modulating lipid and steroid metabolism
JP2022530503A (en) 2019-04-29 2022-06-29 シンロジック オペレーティング カンパニー インコーポレイテッド Genetically engineered microorganisms
CA3142999A1 (en) * 2019-06-13 2020-12-17 Danmarks Tekniske Universitet Advanced microbiome therapeutics engineered to produce serotonin in vivo
CN110331148B (en) * 2019-08-20 2021-05-04 华中农业大学 Gene for coding IFN alpha protein, recombinant vector pELSH-IFN alpha, recombinant lactobacillus casei and application
WO2021092589A1 (en) * 2019-11-08 2021-05-14 The Trustees Of Columbia University In The City Of New York Methods for engineering therapeutics and uses thereof
CN111138513B (en) * 2020-01-06 2022-10-18 天津科技大学 Screening of Cross-Linked peptides of Glutamine transaminase
CN112843096A (en) * 2020-02-11 2021-05-28 青岛东海药业有限公司 Application of clostridium butyricum in preparation of preparation for treating coronavirus infection
WO2021216841A1 (en) * 2020-04-23 2021-10-28 Duke University Compositions and methods for modulating trp channel activity
CN112322528B (en) * 2020-11-03 2022-07-22 江南大学 Lactobacillus rhamnosus capable of intervening metabolic syndrome and application thereof
EP4256039A2 (en) 2020-12-02 2023-10-11 Synlogic Operating Company, Inc. Engineered microorganisms
EP4295859A1 (en) * 2022-06-20 2023-12-27 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Kynurenine aminotransferase and products thereof for the treatment of arthritic diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
DE4232468A1 (en) * 1992-09-28 1994-03-31 Consortium Elektrochem Ind Microorganisms for the production of tryptophan and process for their production
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
WO2012088461A2 (en) 2010-12-23 2012-06-28 Biogen Idec Inc. Linker peptides and polypeptides comprising same
ES2910377T3 (en) * 2012-01-10 2022-05-12 Cj Cheiljedang Corp Escherichia coli microorganisms having improved L-tryptophan production and method for producing L-tryptophan by using the same
US9994809B2 (en) 2012-09-13 2018-06-12 Massachusetts Institute Of Technology Programmable drug delivery profiles of tumor-targeted bacteria
WO2014088982A1 (en) 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
IL250833B (en) 2014-08-29 2022-09-01 Univ Texas Administration of kynurenine depleting enzymes for tumor therapy
WO2016201380A1 (en) 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
CA2988930A1 (en) 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia

Also Published As

Publication number Publication date
WO2017136795A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
MX2021006581A (en) Bacteria engineered to treat diseases associated with hyperammonemia.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016172658A3 (en) Microbiome regulators and related uses thereof
MX2021009673A (en) Modulators of ror-gamma.
EP3668497A4 (en) Methods and compositions for the treatment of diseases associated with cancer, inflammation, or immune response
WO2016183532A8 (en) Bacteria engineered to treat a disease or disorder
EP3526319A4 (en) Compositions and methods for treating diseases and disorders of the central nervous system
MX2019000588A (en) Somatostatin modulators and uses thereof.
WO2019099682A9 (en) Compositions and methods for treating immune disorders using immune modulating lactococcus bacteria strains
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PT3377637T (en) Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2019010949A (en) Somatostatin modulators and uses thereof.
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
EP4031152A4 (en) Methods and probiotic compositions for the treatment of metabolic diseases and disorders
MX2018012902A (en) Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction.
MX2017009417A (en) Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof.
WO2019040106A3 (en) Compounds, salts thereof and their use in the treatment of diseases
EP3507371A4 (en) Methods and compositions for treating diseases and disorders of the nervous system
EP4311577A3 (en) Metalloenzyme inhibitor compounds
EP3570670A4 (en) Compositions and methods for treating lysosomal storage diseases and disorders
MX2017010422A (en) Imidazolyl tricyclic enones as antioxidant iflammation modulators.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17706611

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17706611

Country of ref document: EP

Kind code of ref document: A1